Antioxidant Protein Thioredoxin-1 Reshapes Oligodendrocyte Lineage Cells in Parkinson’s Model

Parkinson’s disease has long been told as a story about dopamine. The canonical narrative holds that neurons producing the neurotransmitter dopamine in a midbrain region called the substantia nigra pars compacta gradually die off, and that clumps of the protein alpha-synuclein accumulate in the surviving cells, spreading toxicity through the circuits that control movement. But a growing body of evidence suggests that this story is incomplete, because another family of brain cells, the oligodendrocytes, appears to be drawn into the pathology as well. A new study published in npj Parkinson’s Disease now reports that the oligodendrocyte lineage responds dynamically to a toxin-based mouse model of Parkinson’s disease, and that a small redox protein called thioredoxin-1 can steer that response.

Oligodendrocytes are best known as the myelin builders of the central nervous system. They wrap neuronal axons in layered membranes of myelin, the fatty insulation that allows electrical signals to travel quickly and reliably, and they also supply metabolic support to the axons they ensheath. Each mature oligodendrocyte can myelinate segments of multiple axons at once, which makes these cells unusually demanding from a metabolic standpoint. Producing and maintaining myelin requires intense lipid synthesis, and lipid-rich membranes are notoriously vulnerable to oxidative damage. That vulnerability matters in Parkinson’s disease, where oxidative stress is considered one of the central destructive forces acting on the vulnerable neurons of the substantia nigra.

The research team, led by Fang Yan and Jie Bai of Kunming University of Science and Technology in China, set out to ask whether thioredoxin-1, a protein already known to protect dopaminergic neurons from the toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine, also influences the oligodendrocyte changes that unfold in the same model. MPTP, as the toxin is abbreviated, is a mainstay of experimental Parkinson’s research. Originally discovered after accidental exposure caused a Parkinson-like syndrome in human drug users, MPTP is converted in the brain into a toxic metabolite called MPP+ that is taken up selectively by dopaminergic neurons, where it sabotages mitochondria and floods cells with reactive oxygen species. The result is a reproducible loss of the same neuronal population that degenerates in patients, along with accumulation of alpha-synuclein.

Thioredoxin-1 sits at the heart of one of the cell’s principal antioxidant systems. It is a small protein that cycles between an oxidized and a reduced form, shuttling electrons to neutralize reactive oxygen species and to keep other protective enzymes, such as peroxiredoxins, in their active states. By maintaining the cellular redox balance, thioredoxin-1 protects proteins, lipids, and DNA from oxidative assault. Earlier work by the same research community had shown that the protein shields dopaminergic neurons from MPTP-induced neurotoxicity, and that it can reduce alpha-synuclein accumulation by promoting the autophagy-lysosome pathway, the cellular waste-disposal machinery that degrades misfolded proteins. The open question was whether these protective effects extend to the oligodendrocyte lineage.

To find out, the researchers treated mice with MPTP to induce Parkinson-like neurodegeneration and then examined the substantia nigra pars compacta, the region most affected in the disease. Using cell-type-specific markers, they tracked the full developmental sequence of the oligodendrocyte lineage: oligodendrocyte progenitor cells, which are the stem-like precursors capable of dividing and migrating; pre-myelinating oligodendrocytes, which have committed to maturation but have not yet wrapped axons; and mature oligodendrocytes, which carry out myelination. They also measured myelin thickness, a direct readout of the insulating capacity of the tissue, and they looked for alpha-synuclein inside oligodendrocytes as well as in dopaminergic neurons.

The findings were striking. Rather than being passively destroyed, the oligodendrocyte lineage responded to MPTP with a coordinated expansion. The number of oligodendrocyte progenitor cells increased, as did the numbers of pre-myelinating oligodendrocytes and mature oligodendrocytes, and myelin thickness in the substantia nigra also grew. This suggests that the myelinating compartment of the midbrain mounts an active, staged response to the toxic insult, ramping up both the production of new lineage cells and the deposition of myelin. Whether this response is protective, compensatory, or in some contexts harmful remains an open question, but its existence demonstrates that Parkinson-like pathology is not confined to neurons. The disease process, at least in this model, remodels an entire glial lineage.

Perhaps the most consequential observation concerned alpha-synuclein. The protein, famous for its role in the neuronal Lewy bodies that define Parkinson’s pathology, was found to accumulate in oligodendrocytes after MPTP treatment, not only in dopaminergic neurons. This is significant because in the human disease, a related condition called multiple system atrophy is characterized precisely by alpha-synuclein aggregates inside oligodendrocytes, known as glial cytoplasmic inclusions. The new data indicate that even in a classical Parkinson model, oligodendrocytes can become a reservoir for the misbehaving protein. Because oligodendrocytes provide metabolic support to neurons and maintain myelin, alpha-synuclein accumulation within them could compromise axonal health and contribute to the circuit dysfunction that produces the motor symptoms of the disease.

Crucially, thioredoxin-1 regulated all of these changes. In mice expressing or supplied with the redox protein, the MPTP-driven increases in oligodendrocyte lineage cells and myelin thickness were modulated, and the accumulation of alpha-synuclein in oligodendrocytes was likewise brought under control. In other words, a single antioxidant protein appears to influence both sides of the glial response: the proliferation and maturation dynamics of the oligodendrocyte lineage, and the protein aggregation burden within those cells. The authors interpret this as evidence that the oligodendrocyte alterations seen in MPTP-induced Parkinson’s mice are not incidental but are actively shaped by the cellular redox environment, and that thioredoxin-1 is a key regulator of that environment.

The mechanistic logic is plausible in light of what is known about both cell types. MPTP toxicity generates oxidative stress that would be expected to damage myelin membranes and to impair the protein quality-control systems that normally clear misfolded alpha-synuclein. Thioredoxin-1, by buffering reactive oxygen species and by supporting autophagy-lysosomal degradation, could simultaneously relieve the pressure that drives lineage expansion and the pressure that permits protein aggregation. If oligodendrocytes proliferate in response to myelin damage, reducing that damage at its source would reduce the perceived need for repair. If alpha-synuclein accumulates because clearance systems are overwhelmed, boosting those systems would restore balance. The study’s results are consistent with both mechanisms operating through a shared redox-sensitive hub.

For the Parkinson’s field, the work widens the therapeutic aperture. Most neuroprotective strategies have aimed squarely at dopaminergic neurons, and the idea of supporting oligodendrocytes has been explored mainly in the context of multiple sclerosis and other demyelinating diseases. This study suggests that in Parkinson’s disease, the myelinating cells of the substantia nigra are participants in the pathology and potential targets for intervention. A therapy that bolsters thioredoxin-1 activity, or mimics its effects, could in principle protect neurons and glia at the same time, addressing the oxidative stress and protein aggregation that cut across cell types. The researchers acknowledge that their findings come from the MPTP model, which reproduces key features of the disease but does not capture its full complexity, and that translating redox biology from mice to patients remains a formidable challenge. Still, the demonstration that a well-characterized antioxidant protein orchestrates the oligodendrocyte response to Parkinson-like injury adds a new dimension to a disease that science has been trying to see whole. The cells that insulate the brain’s wiring, it turns out, are not bystanders in Parkinson’s disease. They are players, and thioredoxin-1 may hold one of the controls.

Subject of Research: Effects of thioredoxin-1 on oligodendrocyte lineage cells and alpha-synuclein accumulation in an MPTP mouse model of Parkinson's disease

Article Title: Effects of thioredoxin-1 on oligodendrocyte lineage cells altered by the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine

Article References: Yan, F., Xia, Q., Sun, X., Duan, J., Gu, R., Pan, Y., Bai, L., Li, Y., Zhang, X., & Bai, J. (2026). Effects of thioredoxin-1 on oligodendrocyte lineage cells altered by the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. npj Parkinson's Disease. https://doi.org/10.1038/s41531-026-01581-8

Image Credits: AI Generated

DOI: 10.1038/s41531-026-01581-8

Keywords: Parkinson's disease, thioredoxin-1, oligodendrocytes, MPTP, alpha-synuclein, substantia nigra, myelin, oxidative stress, oligodendrocyte progenitor cells, neurodegeneration, redox biology, dopaminergic neurons